Muthu Veeraputhiran
Title | Associate Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Internal Med, College of Medicine |
---|
Division | Internal Med Hem-Onc |
---|
Address | 4104 Outpatient Circle Mail Slot # 508 Little Rock AR 72205
|
---|
Phone | 501-686-8511 |
---|
vCard | Download vCard |
---|
|
|
|
Overview Dr. Muthu Veeraputhiran is a physician in the University of Arkansas for Medical Sciences (UAMS) Department of Internal Medicine. Dr. Veeraputhiran received his medical degree from the Stanley Medical College in his native India. He went on to receive a Masters of Public health from the University of Oklahoma. He then completed residency training in Internal Medicine at Abington Memorial Hospital in Pennsylvania. He has also completed fellowships in Transfusion Medicine at UAMS, Hematology, Oncology, and Bone Marrow Transplantation at Wayne State University, and Bone Marrow Transplantation at Stanford University. Dr. Veeraputhiran is board certified in Clinical Cardiac Electrophysiology from the American Board of Internal Medicine. He is a member of several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Association for Blood Banks, the American Board of Internal Medicine, the American Society of Hematology, and the American Society of Oncology.
Research UAMS C25144 (KUMARAN, MUTHU K)Sep 6, 2022 - Sep 5, 2023 AbbVie Inc A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T) Role: Principal Investigator |
| UAMSC25144 (KUMARAN, MUTHU K)Sep 6, 2022 - Sep 5, 2023 AbbVie Inc A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T) Role: Principal Investigator |
| UAMS C24929 (KUMARAN, MUTHU K)Aug 17, 2022 - Aug 16, 2023 Gilead Sciences, Inc. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed... Role: Principal Investigator |
| UAMSC24929 (KUMARAN, MUTHU K)Aug 17, 2022 - Aug 16, 2023 Gilead Sciences, Inc. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed... Role: Principal Investigator |
| U3UHS45467 (MCELFISH, PEARL A)Feb 1, 2022 - Oct 31, 2023 Health Resources & Services Administration The Vaccine REACH (Reaching Everyone to Achieve Community Health) project Role: Principal Investigator |
| CPIMP211231 (MCELFISH, PEARL A)Jul 1, 2021 - Jun 30, 2024 DHHS - Office of Minority Health - Pass Through: Benton County Government Benton County REACH Covid Health Literacy Role: Principal Investigator |
| INCB39110-309 (KUMARAN, MUTHU K)Mar 27, 2020 - Mar 26, 2021 Incyte Corporation GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545) Role: Principal Investigator |
| INCB39110 (VEERAPUTHIRAN, MUTHU)Mar 27, 2020 Incyte Corporation GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545) Role: Principal Investigator |
| A041701 (KUMARAN, MUTHU K)Jul 30, 2019 NIH/Nat. Cancer Institute - Pass Through: Alliance for Clinical Trials in Oncology No FP attached Role: Principal Investigator |
| KD025 (VEERAPUTHIRAN, MUTHU)Jul 26, 2019 Kadmon Corporation, LLC A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study) (IRB# 239363) Role: Principal Investigator |
| KD025-213 (KUMARAN, MUTHU K)Jul 26, 2019 Kadmon Corporation, LLC No FP attached Role: Principal Investigator |
| M16 (VEERAPUTHIRAN, MUTHU)Jul 26, 2019 AbbVie Inc Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (IRB 228481) Role: Principal Investigator |
| M16-183 (KUMARAN, MUTHU K)Jul 26, 2019 AbbVie Inc No FP attached Role: Principal Investigator |
| AG-348-C-008 (KUMARAN, MUTHU K)Jul 27, 2018 Agios Pharmaceuticals, Inc. No FP attached Role: Principal Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2024 Oct 17; JCO2400321. PMID: 39418622.
-
Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. Blood Adv. 2024 Aug 02. PMID: 39093952.
-
Pusic I, Lee C, Veeraputhiran M, Minor C, DiPersio JF. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2024 02; 59(2):282-284. PMID: 38071272.
-
Fugere T, Baltz A, Mukherjee A, Gaddam M, Varma A, Veeraputhiran M, Gentille Sanchez CG. Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity. Cancers (Basel). 2023 Oct 26; 15(21). PMID: 37958323.
-
Lopez-Candales A, Mathur P, Mounsey JP, Veeraputhiran M. Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? Postgrad Med. 2022 Jan; 134(1):7-10. PMID: 34664532.
-
Roy AM, Pandey Y, Middleton D, Broadfoot B, Sasapu A, Veeraputhiran M. Intravascular Large B-Cell Lymphoma: A Diagnostic Dilemma. Cureus. 2021 Jul; 13(7):e16459. PMID: 34422488.
-
Kakadia S, Trotta H, Kurczek L, Burdine L, Veeraputhiran M, Giorgakis E. Early Outcomes of Ruxolitinib in the Treatment of Steroid Refractory Graft-versus-host Disease on Liver Transplant Recipients. Transplantation. 2020 08; 104(8):e247. PMID: 32732859.
-
Kothari A, Caradine KD, Rico Crescencio JC, Sasapu A, Veeraputhiran MK, Jethava Y, Burgess MJ. Cytomegalovirus appendicitis after hematopoietic stem cell transplantation. Transpl Infect Dis. 2017 Oct; 19(5). PMID: 28708253.
-
Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng WK, Johnston L. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1744-1748. PMID: 28668491.
-
Kaur V, Swami A, Shebli A, Shalin S, Veeraputhiran M, Emanuel P, Jethava Y. A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy. J Oncol Pharm Pract. 2017 Oct; 23(7):552-556. PMID: 27559020.
-
Nandagopal L, Veeraputhiran M, Jain T, Soubani AO, Schiffer CA. Bronchoscopy can be done safely in patients with thrombocytopenia. Transfusion. 2016 Feb; 56(2):344-8. PMID: 26446048.
-
Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):531-5. PMID: 26166312.
-
Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, Deol A. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. J Clin Apher. 2014 Dec; 29(6):293-8. PMID: 24700728.
-
Veeraputhiran M, Katragadda L, Balamurugan A, Cottler-Fox M. Aldehyde dehydrogenase as an alternative to enumeration of total and viable CD34(+) cells in autologous hematopoietic progenitor cell transplantation. Cytotherapy. 2011 Nov; 13(10):1256-8. PMID: 21905957.
-
Veeraputhiran MK, Pesek GA, Blackall DP. Strict vs lenient criteria for elution testing: comparison of yields between two tertiary care medical centers. Am J Clin Pathol. 2011 Sep; 136(3):359-63. PMID: 21846910.
-
Veeraputhiran M, Ware J, Dent J, Bornhorst J, Post G, Cottler-Fox M, Pesek G, Theus J, Nakagawa M. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion. 2011 May; 51(5):1030-6. PMID: 20946201.
-
Veeraputhiran M, Theus JW, Pesek G, Barlogie B, Cottler-Fox M. Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration. Cytotherapy. 2010 Oct; 12(6):764-6. PMID: 20353307.
-
Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer. 2008 Jul; 9(4):232-4. PMID: 18650173.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2008 | 1 | 2010 | 2 | 2011 | 2 | 2014 | 1 | 2015 | 2 | 2016 | 1 | 2017 | 2 | 2020 | 1 | 2021 | 2 | 2023 | 2 | 2024 | 2 |
To return to the timeline, click here.
|
Veeraputhiran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|